OpenClaim

Emapalumab Side Effects

The most commonly reported side effects of emapalumab include off label use, haemophagocytic lymphohistiocytosis, and condition aggravated, based on 428 FDA adverse event reports from 2013 to 2025. 14.7% of reports found the drug to be ineffective.

#1 Reported: Off Label UseAll side effects ↓Top Co-Medication: AnakinraDrug interactions ↓26% of Reports Are AdultDemographics ↓

Emapalumab side effects

Percentages show how often each reaction appears relative to total reports for emapalumab.

1
Off Label Use37.4%160
2
Haemophagocytic Lymphohistiocytosis21.5%92
3
Condition Aggravated18.5%79
4
Drug Ineffective14.7%63
5
Multiple Organ Dysfunction Syndrome7.7%33
6
Septic Shock6.5%28
7
Pyrexia6.5%28
8
Death6.1%26
9
Epstein-barr Virus Infection5.6%24
10
Respiratory Failure5.4%23
11
Adenovirus Infection5.1%22
12
Staphylococcal Bacteraemia4.4%19
13
Disseminated Intravascular Coagulation4.2%18
14
Drug Ineffective For Unapproved Indication4.0%17
15
Drug Reaction With Eosinophilia And Systemic Symptoms4.0%17

These are voluntary reports and do not establish that emapalumab caused these reactions.

Report severity

89.0%Serious381 reports
38.3%Hospitalizations164 reports
35.5%Fatal152 reports

Seriousness is determined by the reporter, not by OpenClaim.

Emapalumab drug interactions

Other drugs that appear in adverse event reports alongside emapalumab. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.

Also suspected

1
Anakinra36.2%155
2
Dexamethasone26.4%113
3
Etoposide24.1%103
4
Methylprednisolone18.2%78
5
Ruxolitinib17.1%73
6
Cyclosporine14.0%60
7
Cyclophosphamide12.6%54
8
Tocilizumab12.6%54
9
Rituximab10.7%46
10
Prednisolone8.6%37
11
Prednisone7.2%31
12
Tacrolimus7.2%31
13
Fludarabine-phosphate6.3%27
14
Canakinumab5.8%25
15
Hydrocortisone4.4%19

Taken alongside

1
Acyclovir11.7%50
2
Dexamethasone10.3%44
3
Anakinra8.2%35
4
Methylprednisolone7.2%31
5
Meropenem6.8%29
6
Amphotericin-b5.6%24
7
Etoposide4.9%21
8
Canakinumab4.9%21
9
Ruxolitinib4.7%20
10
Fludarabine-phosphate4.7%20
11
Rituximab4.4%19
12
Fluconazole4.2%18
13
Pentamidine-isethionate4.2%18
14
Furosemide4.2%18
15
Cyclosporine4.0%17

Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.

Who reports emapalumab side effects

39.5% of emapalumab adverse event reports involve female patients and 44.9% involve male patients. The largest age group is adult at 26%. These figures reflect who reports side effects, not underlying risk.

Sex

Female39.5%
Male44.9%
Unknown15.7%

Age group

< 223.5%
2–1125.6%
12–1716.8%
18–6426.5%
65+7.6%

What is emapalumab used for

Conditions and purposes for which patients were taking emapalumab when the adverse event was reported.

Alveolar ProteinosisAnaplastic Large Cell Lymphoma T- And Null-cell TypesAutoinflammatory DiseaseBone Marrow DisorderBone Marrow TransplantCovid-19Chediak-higashi SyndromeCondition AggravatedCytogenetic AbnormalityCytokine Release SyndromeCytokine StormEpstein-barr Virus InfectionEpstein-barr Virus Associated LymphomaEpstein-barr Virus InfectionFamilial Haemophagocytic Lymphohistiocytosis

Showing 15 of 51 indications

Emapalumab brand names and reporting trend

Emapalumab is sold under the brand name Gamifant.

Brand names

Gamifant478

Quarterly reports (2013–2025)

2013202020242025

An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.

Taking emapalumab with another medication?

Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.

Check my medications